pocketful logo light
pocketful logo light
Fredun Pharmaceuticals Ltd logo

Fredun Pharmaceuticals Ltd

NSE: BSE: 539730

₹1492.70

(0.34%)

Fri, 11 Sept 2026, 03:11 pm

Fredun Pharmaceuticals PE Ratio

Particulars2015201620172018201920202021202220232024
Price to earnings ratio2.7810.0527.9136.5124.4591.8081.1533.9021.5815.72
Price to book ratio0.803.012.214.331.134.295.963.662.772.23
Price to sales ratio0.070.250.841.680.411.382.311.340.970.68
Price to cash flow ratio1.685.813.240000000
Enterprise value17.37Cr34.5Cr60.06Cr187Cr78.29Cr223Cr565Cr449Cr440Cr473Cr
Enterprise value to EBITDA ratio4.158.8413.1118.039.3823.7940.6716.0511.548.78
Debt to equity ratio3.922.530.570.660.840.920.780.900.871.19
Return on equity %025.4411.9014.594.744.7711.4013.1414.3415.02

Fredun Pharmaceuticals Ltd Price to Earnings Ratio

The Fredun Pharmaceuticals Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Fredun Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Fredun Pharmaceuticals Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Fredun Pharmaceuticals Ltd (NSE: , BSE: 539730) is currently trading at ₹1492.70, with a market capitalization of ₹2403.23Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Fredun Pharmaceuticals Ltd Price to Earnings Ratio is essential for fundamental analysis.

Fredun Pharmaceuticals Ltd Price to Earnings Ratio Current Value

The current Fredun Pharmaceuticals Ltd Price to Earnings Ratio stands at 15.72.

The Fredun Pharmaceuticals Ltd Price to Earnings Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.

Fredun Pharmaceuticals Ltd Price to Earnings Ratio Historical Trend

The Fredun Pharmaceuticals Ltd Price to Earnings Ratio has shown the following historical trend:

  • 2024: 15.72
  • 2023: 21.58
  • 2022: 33.90
  • 2021: 81.15
  • 2020: 91.80

The decline in Fredun Pharmaceuticals Ltd Price to Earnings Ratio indicates improving financial efficiency or better earnings growth.

What Fredun Pharmaceuticals Ltd Price to Earnings Ratio Indicates for Investors

The Fredun Pharmaceuticals Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.

A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.

Fredun Pharmaceuticals Ltd Price to Earnings Ratio Analysis Summary

The Fredun Pharmaceuticals Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Fredun Pharmaceuticals Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Fredun Pharmaceuticals Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.

Open Your Free Demat Account

Enter your phone number